Key Highlights
- Revolution Medicines shares rose 5.91% pre-market today to $211.50, from a prior close of $199.70.
- Daraxonrasib generated $197.6 million in net product Revenue over about five weeks of sales, against an estimate of $25.6 million.
- More than 5,000 unique patients were treated, with about 2,700 prescribers across academic and community settings.
- The adjusted loss was $1.90 per share versus an expected loss of $2.34.
- Cash stood at $3.7 billion, excluding a $250 million Debt Tranche received in October.
Revolution Medicines (NASDAQ:RVMD) shares rose in pre-market activity today after the company reported its first commercial quarter for daraxonrasib, which was approved on August 26 for previously treated metastatic pancreatic cancer. The stock changed hands at $211.50, up 5.91% from Wednesday's close of $199.70, which followed a 2.82% gain in the regular session.
Revolution Medicines is a Redwood City, California-based oncology company developing oral targeted therapies for RAS-addicted cancers, including pancreatic, lung and colorectal tumors. Its pipeline is built on a proprietary tri-complex platform that produces RAS(ON) inhibitors.
Management cautioned that early sales included finite groups of patients, such as expanded-access transitions and a Backlog awaiting approval, along with some channel stocking, so the launch run-rate should not be extrapolated.
A Five-Week Launch Quarter Draws Backlog Patients and New Starts
Net product revenue of $197.6 million came from about five weeks of sales and more than 5,000 unique patients, against a consensus of roughly $25 million to $27 million.
Channel inventory ended the quarter below two weeks, against a long-term target of about two weeks. Gross-to-net discount sat at the low end of a 20% to 30% range and is expected to rise within it. Claims were reimbursed across plans covering more than 90% of U.S. pancreatic cancer lives, and prescribing split about 40% academic and 60% community across roughly 2,700 prescribers.
Spending Surges as the Net Loss Widens to $407.5 Million
Research and development expense rose to $417.1 million from $262.5 million a year earlier, and selling, general and administrative expense rose to $153.3 million from $52.8 million. The net loss was $407.5 million, including a $40.7 million non-cash Warrant charge. Cash was $3.7 billion, excluding a $250 million debt tranche received in October. Up to $1 billion in optional committed Capital remains, and the company declined an optional Royalty tranche.
Full-year 2026 GAAP operating expenses are guided to $2.1 billion to $2.2 billion, including $270 million to $290 million of stock-based compensation. Management expects 2027 operating expenses to rise above the current run rate on pipeline Investment and global commercial expansion, without a specific range. The company carries a market Capitalization of about $42.8 billion and a loss of $8.82 per share, and its 52-week range runs from $58.00 to $224.31.
Europe Decision, Japan Readiness and Phase 3 Readouts Fill the Calendar
The European Medicines Agency's CHMP issued a positive opinion, with a European Commission decision pending, and Japan launch readiness is advancing. The NCCN gave daraxonrasib a Category 1 preferred listing in pancreatic cancer, and the FDA granted breakthrough designation for first-line use with chemotherapy.
Enrollment in the RASolute 303 study is expected to finish in the first half of 2027, and the RASolve 301 lung cancer Phase 3 readout is planned for 2027. A colorectal clinical data update is expected in the first half of 2027, and initial RMC-5127 monotherapy data in 2027.
European Approval and Fourth-Quarter Demand Set the Next Test
The next tests are the European Commission decision and whether demand holds once the expanded-access transitions and approval backlog are worked through.






Please wait processing your request...